1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Immuno-Oncology Overview

Immuno-Oncology Overview

  • June 2015
  • -
  • Datamonitor Healthcare

This is an overview of the field of immuno-oncology and the various immuno-oncology classes Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions


Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types, and that this class will be the most commercially successful immuno-oncology class over the next 10 years As monotherapies, PD-1 inhibitors will become the first-line treatment of choice in melanoma, and they are also likely to gain further approvals for a wide variety of cancers

CAR-T cell therapy early clinical results are extremely promising The leading CD19-targeted CAR-T treatments from Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphoblastic leukemia

Expectations for cancer vaccines have diminished after multiple failures In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure

What’s included in this report?

Three fully transcribed key opinion leader interviews

Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class

10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446

Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development

Key questions answered:

What are the key immuno-oncology products in development?

What important clinical trial results have been reported for drugs in each immuno-oncology drug class?

What specific targets and therapy approaches are the developers in this field focusing on?

What factors could limit the commercial potential of immuno-oncology drugs in development?

What recent deals have taken place that are related to the field of immuno-oncology?

Table Of Contents

Immuno-Oncology Overview
Immuno-oncology overview6
CD40 71
CAR-T cell therapy75
T-cell receptor gene therapy86
Dendritic cell therapy90
CEA 104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6 995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Ovarian Cancer: Analytical Tool

August 2016 $ 7 125

Download Unlimited Documents from Trusted Public Sources

Ovarian Cancer Statistics in the UK

  • October 2016
    39 pages
  • Ovarian Cancer  



  • United Kingdom  


View report >

Cancer Statistics in the US

  • October 2016
    9 pages
  • Pathology  


  • United States  

View report >

Cancer Statistics in the US and North America, Weekly Update

  • October 2016
    88 pages
  • Cancer  

  • United States  

    North America  

View report >

Related Market Segments :

Cell Therapy
Gene Therapy


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.